A New Kind Of Treatment

Kalos Therapeutics

Market Potential for the Kalos Platform of Drugs

Kalos Therapeutics

Cancer is the second major cause of death in the US. The global cancer market was valued at $47.5 billion in 2005 and sales of oncology drugs were forecasted by IMS Health to rise to $60.0 billion in 2010. The estimated cost of treating pancreatic cancer is $1.5 billion in the US alone and is projected to grow to $1.8 billion by 2020. The approximately 15,000 US oncologists can be accessed with a limited sales force.

Retinal disease, there exists a global macular degeneration market which was valued at over one billion dollars in 2009, and is expected to double by 2016 due to the aging of the population. These values are based largely on treatments that are given to patients after the development of wet AMD. This market could be considerably expanded if a drug was to become available that offered sufficient safety and ease of administration to be used prophylactically.

Potential animal health markets are also targets for the company based on the clinically demonstrated increase of diuresis and cell inhibition that have applications for products in animal health for diseases affecting the cardio-renal system. Use in the Equine industry to replace Lasix is an initial target indication. Additional markets include companion animal diseases such as congestive heart failure, feline kidney disease and cancer.

Strong Intellectual property

Strong Intellectual Property Portfolio

Kalos has patent applications covering both composition and the use of peptides containing our ACM motif in cancer applications. We are currently filing additional patent applications to enhance the strength of our IP portfolio.